- High blood pressure is a risk factor for cognitive decline and dementia in older adults.
- Studies have shown that commonly prescribed high blood pressure medications, or antihypertensives, may have a positive, beneficial impact on cognitive function including memory.
- This is the first meta-analysis to compare the impact on memory over time associated with taking antihypertensives that cross the blood-brain barrier versus those that do not.
- Researchers found that older adults taking antihypertensive medications that cross the blood-brain barrier, such as angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers, had better memory recall over time compared to people taking other types of antihypertensive medicines.
Embargoed until 4 a.m. CT/5 a.m. ET Monday, June 21, 2021
DALLAS, June 21, 2021 — Older adults taking blood pressure-lowering medications known to cross the blood-brain barrier had better memory recall over time compared to those taking other types of medicines to treat high blood pressure, according to new research published today in the American Heart Association journal Hypertension.
High blood pressure, or hypertension, is a risk factor for cognitive decline and dementia in older adults. Nearly half of American adults have elevated blood pressure. Treating high blood pressure with blood pressure-lowering medicines reduced the cases of mild cognitive impairment by 19% in one large trial (SPRINT MIND).
ACE inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers and diuretics are different classes of blood pressure-lowering medicines. Each class acts in a different way to reduce blood pressure, and some cross the blood-brain barrier, thereby impacting cognitive function.
“Research has been mixed on which medicines have the most benefit to cognition,” said study author Daniel A. Nation, Ph.D., an associate professor of psychological science in the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine. ”Studies of angiotensin II receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors have suggested these medicines may confer the greatest benefit to long-term cognition, while other studies have shown the benefits of calcium channel blockers and diuretics on reducing dementia risk.”
This is the first meta-analysis to compare the potential impact over time of blood pressure lowering medicines that do vs. those that do not cross the blood-brain barrier. The medicines were evaluated for their effects on several cognitive domains, including attention, language, verbal memory, learning and recall.
“Hypertension occurs decades prior to the onset of dementia symptoms, affecting blood flow not only in the body but also to the brain,” Nation said . “Treating hypertension is likely to have long-term beneficial effects on brain health and cognitive function later.”
Researchers gathered information from 14 studies of nearly 12,900 adults ages 50 years and older. These included studies done in the United States, Australia, Canada, Germany, Ireland and Japan. The meta-analysis found:
- Older adults taking blood pressure-lowering medicines that cross the blood-brain barrier had better memory recall for up to 3 years of follow-up compared to those taking medicines that do not cross the blood-brain barrier even though they had a higher level of vascular risk.
- Adults taking hypertension medications that did not cross the blood-brain barrier had better attention for up to 3 years of follow-up.
“These findings represent the most powerful evidence to-date linking brain-penetrant ACE-inhibitors and angiotensin receptor blockers to better memory. It suggests that people who are being treated for hypertension may be protected from cognitive decline if they medications that cross the blood-brain barrier,” said study co-author Jean K. Ho, Ph.D., a postdoctoral fellow at the University of California, Irvine.
Blood pressure is considered elevated at 120/80 mm Hg and higher. The current American Heart Association/American College of Cardiology guidelines for treating high blood pressure suggest changes to diet and activity levels to lower blood pressure and adding blood pressure-lowering medication for people with levels of 130/80 mm Hg or higher depending on their risk status. If blood pressure reaches 140/90 mm Hg, blood pressure-lowering medication is recommended.
Limitations of this analysis are that the authors could not account for differences in racial/ethnic background based on the available studies, and there is a higher proportion of men vs. women in the group who took medications that cross the blood-brain barrier. This is an important area of future research since previous studies have shown that people from various racial/ethnic backgrounds may respond differently to different blood pressure medications.
Co-authors are Frank Moriarty, Ph.D.; Jennifer J. Manly, Ph.D.; Eric B. Larson, M.D., M.P.H.; Denis A. Evans, M.D.; Kumar B. Rajan, Ph.D.; Elizabeth M. Hudak, Ph.D.; Lamiaa Hassan, M.Sc.; Enwu Liu, Ph.D.; Nobuyuki Sato, M.D., Ph.D.; Naoyuki Hasebe, M.D., Ph.D.; Danielle Laurin, Ph.D.; and Pierre-Hugues Carmichael, M.Sc.
The National Institute on Aging of the National Institutes of Health, and the Alzheimer's Association funded this study. A full list of funding sources for the 14 individual studies within the meta-analysis are available in the manuscript.
- Available multimedia is on right column of release link - https://newsroom.heart.org/news/some-blood-pressure-lowering-meds-linked-to-less-memory-decline-in-older-adults?preview=895a413bff25584f9e4632bee0621a2c
- After June 21, view the manuscript online.
- Learn more about high blood pressure at heart.org/hbp.
- Understanding blood pressure readings
- Health threats from high blood pressure
- High blood pressure tools and resources
- American Heart Association awarded HHS funding for hypertension control
- Follow AHA/ASA news on Twitter @HeartNews
- Follow news from the AHA’s Hypertension journal @HyperAHA
Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Maggie Francis: email@example.com; 214-706-1382
For Public Inquiries: 1-800-AHA-USA1 (242-8721)